08:00 , Dec 8, 2008 |  BC Week In Review  |  Company News

BioPro, Ranbaxy sales and marketing update

BioPro granted Ranbaxy exclusive rights to market Gliadel Wafer carmustine implant in India to treat newly diagnosed high-grade glioma and recurrent glioblastoma multiforme (GBM). BioPro has rights to market the biodegradable polymer implant containing carmustine...
08:00 , Jan 2, 2006 |  BC Week In Review  |  Company News

BioPro, Nexmed Medical Co. Ltd. deal

Cancer company BioPro acquired 80% of distribution company Nexmed for an undisclosed sum. BioPro said that Nexmed, which will be named BioPro Pharmaceutical China Ltd., is expected to post 2005 revenues of $9 million. BioPro...